Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 3-year extension study of tinlarebant in Stargardt disease
2025-522460-33-00Phase 3Authorised
- Sponsor
- Belite Bio, Inc
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of tinlarebant in Fundus Flavimaculatus (FF), sponsored by Belite Bio, Inc. Primary endpoints: Change in DDAF by FAF, Change in QDAF by FAF and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2025-522460-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522460-33-00.